Article Text

PDF
A survey of palivizumab for infants with cystic fibrosis in the UK
  1. J McCormick1,
  2. K W Southern2
  1. 1Respiratory Unit, Royal Hospital for Sick Children, Yorkhill NHS Trust, Glasgow, UK
  2. 2Institute of Child Health, Alder Hey Children’s Hospital, University of Liverpool, Liverpool, UK
  1. Correspondence to:
    J McCormick
    Respiratory Unit, Royal Hospital for Sick Children, Yorkhill NHS Trust, Dalnair Street, Glasgow G3 8SJ, UK;jdmccormick{at}btinternet.com

Statistics from Altmetric.com

Palivizumab is a humanised monoclonal antibody to respiratory synctial virus (RSV) that has been advocated as a potential prophylactic treatment in at-risk infants (ex-preterm).1 Infection with RSV in cystic fibrosis may be a factor in the development of early lung disease and acquisition of bacterial pathogens. We aimed to determine the number of infants with cystic fibrosis in the UK who would be potential candidates for palivizumab prophylaxis and to quantify hospitalisation rates and mortality from RSV in this cohort. We conducted a national questionnaire study of 42 cystic fibrosis centres over the winter RSV season of 2005–6. Data were sought on patient population (number of infants born after October 2004), admissions with …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.